Amsacrine and cisplatin in poor prognosis patients with metastatic transitional cell carcinoma of the urothelium: A phase-II study

European Urology

Volumn 40, Issue 3, 2001, Pages 324-329

  Popov, Ivan ^a   Jelic S ^a   Radosavljevic D ^a   Nikolic Tomasevic Z ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Amsacrine; Cisplatin; Metastatic disease; Urothelial carcinoma

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CISPLATIN;

ADULT; AGED; ANEMIA; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AMSACRINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 0035743203     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049794     Document Type: Article

References (28)

1. The treatment of advanced bladder cancer
2. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma
3. Long term follow up phase III intergroup study of M-VAC vs. cisplatin in metastatic urothelial carcinoma
4. Survival of patients with advanced urothelial cancer treated with cisplatin based therapy
5. Amsacrine: A new drug for hematological malignancies
6. Investigational agents-Am-sacrine
7. Chemotherapy for advanced bladder cancer
8. Phase II trial of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: A Southwest Oncology Group study
9. Reporting results of cancer treatment
10. High dose AMSA and autologous bone marrow transplantation (ABMT) in patients with solid tumors
11. Phase II study of high dose AMSA and autologous bone marrow transplantation in patients with refractory metastatic breast cancer
12. A review of clinical data
13. Chemotherapy for urothelial tract cancer
14. A two-step reevaluation of high-dose amsacrine for advanced carcinoma of the upper aerodigestive tract: A pilot phase II study
15. Cancer of the bladder
16. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) plus GM-CSF in patients with advanced transitional cell carcinoma: An ECOG trial
17. M-VAC versus the same combination using epirubicin at duble dose (M-VEEC) in locally invasive bladder cancer. A prospective study
18. 5-Fluorouracil, interferon-alfa-2b and cisplatin (FAP) for advanced urothelial cancer. A phase II study
19. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy
20. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy
21. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma
22. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regimen
23. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma
24. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial
25. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial
26. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group
27. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
28. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: Results of large, randomized, multinational, multicenter, phase III study